艾伯维(ABBV.US)承诺在美投资千亿美元 以换取关税豁免

Core Viewpoint - AbbVie (ABBV.US) has signed an agreement with the U.S. government to lower certain drug prices and invest $100 billion in domestic operations in exchange for specific tariff exemptions [1] Group 1: Agreement Details - The agreement responds to four key demands from the Trump administration, including providing low-cost drugs for the Medicaid program, selling affordable drugs directly to patients, and ensuring that overseas drug prices do not fall below U.S. domestic prices [1] - AbbVie will invest the $100 billion over the next ten years in U.S. research and capital expenditure projects, including drug manufacturing [1] - The company has not yet provided details on the specific allocation of the $100 billion investment [1] Group 2: Pricing and Compliance - AbbVie will lower drug prices within the Medicaid program and supply certain drugs directly to patients through the "TrumpRx" website launched by the Trump administration [1] - In return for these commitments, AbbVie will receive tariff exemptions and will be exempt from future mandatory drug pricing policies [1]